Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 4/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17882022 | 0.87 | PRKCA (0.44) | CTSKALDH1A1SMN1; SMN2TSHRCA1 | |
| SCHEMBL12369638 | 0.86 | MAPT (0.42) | PRKCAPRKCD | |
| SCHEMBL29538930 | 0.84 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNAPRKCA | |
| SCHEMBL7217575 | 0.84 | CTSK (0.39) | CTSK | |
| SCHEMBL17515451 | 0.82 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL13541326 | 0.82 | TSHR (0.43) | ALDH1A1LMNAHSD17B10TSHRCA1 | |
| SCHEMBL580557 | 0.82 | TSHR (0.43) | ALDH1A1LMNAHSD17B10TSHRCA1 | |
| SCHEMBL1866475 | 0.82 | TSHR (0.43) | ALDH1A1LMNAHSD17B10TSHRCA1 | |
| SCHEMBL827371 | 0.82 | CTSK (0.35) | CTSKALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL17617132 | 0.82 | TSHR (0.43) | ALDH1A1LMNAHSD17B10TSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | APTINYX INC (US) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | ACE, ACE2, PREP | CTSK 71/4885ALDH1A1 1618/4885SMN1; SMN2 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.